NCT06142695

Brief Summary

The aim of the study was to evaluate the efficacy of vaginal Carbon Dioxide Laser treatment in patients with Genitourinary Syndrome of Menopause on the improvement of Vulvovaginal Atrophy (VVA) and stress urinary incontinence (SUI) by objective parameters and in particular to assess the ultrasound measurement of specific vaginal parameters in order to evaluate a new objective tool of assessment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 11, 2021

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 12, 2021

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 9, 2022

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 18, 2023

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 21, 2023

Completed
Last Updated

November 21, 2023

Status Verified

November 1, 2023

Enrollment Period

11 months

First QC Date

July 18, 2023

Last Update Submit

November 20, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Evaluating the effectiveness of Carbon Dioxide Laser in patients with genitourinary syndrome of menopause in terms of the improvement in a specific vaginal ultrasonographic parameters

    To evaluate the primary outcome, we examined the following vaginal ultrasonographic parameters (by transvaginal probe), both before and after 3 vaginal Carbon Dioxide Laser applications: * Thickness of the anterior vaginal walls (VWT) at the level of the introitus of the inferior vaginal third (expressed in millimeters); * Thickness of the posterior VWT at the level of the introitus of the inferior vaginal third (expressed in millimeters). Positive outcomes are evidenced if thickness (expressed in millimeters) is increased after treatment in both anterior and posterior vaginal walls.

    4 months

Eligibility Criteria

Age45 Years - 75 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Menopausal patients that attended our clinic of menopausal disorders and performed Carbon Dioxide Laser therapy for genitourinary syndrome. In order to enroll patients with Genitourinary Syndrome of Menopause, the investigator used the Vaginal Health Index (VHI), Vulvar Health Index (VuHI), and Stress Urinary Incontinence (SUI) scales. * The VHI score assesses vaginal health, with a cutoff of \<15 on the index to diagnose patients with atrophy \[ranging from "complete atrophy" (0) to "optimal vaginal health" (25)\]. * The VuHI score assesses vulvar health, on a scale from normal (0) to severe (3). The overall score ranges from 0 to 24, and its cutoff for diagnosing atrophic vulva is \>8 on the index. * Stress Urinary Incontinence (SUI) is characterized by sudden urine loss. Evaluated using the Stamey score, with ratings of no incontinence (0) to severe incontinence (3).

You may qualify if:

  • Age \<75 years, menopause (naturally, pharmacologically or surgically induced, at least 12 months)
  • Negative Papanicolaou test (PAP) performed within 12 months before enrolment. and one of the following:
  • Presence of vulvovaginal atrophy \[vaginal health index (VHI) \< 15\]
  • Initial Urinary Incontinence based on patient history = 1 (according to the "Stamey incontinence score of Stress Urinary Incontinence" - min. 0 = no incontinence, max. 3 = severe incontinence)
  • Standardized stress provocation test

You may not qualify if:

  • Age \>45 years
  • The presence of vaginal lesions (active or in the previous 30 days).
  • genitourinary tract infection.
  • abnormal uterine bleeding.
  • use of hormone replacement therapy up to 6 months before enrolment.
  • history of photosensitivity disorder or use of photosensitizing drugs.
  • genitals prolapse (grade II - III according to the Pelvic Organ Prolapse Quantification)
  • a serious or chronic condition that could interfere with study compliance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

FPG gemelli RCCS

Rome, Lazio, 00168, Italy

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

July 18, 2023

First Posted

November 21, 2023

Study Start

January 11, 2021

Primary Completion

December 12, 2021

Study Completion

January 9, 2022

Last Updated

November 21, 2023

Record last verified: 2023-11

Locations